<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742573</url>
  </required_header>
  <id_info>
    <org_study_id>#5692</org_study_id>
    <secondary_id>R01MH076051</secondary_id>
    <secondary_id>DSIR 83-ATSO</secondary_id>
    <nct_id>NCT00742573</nct_id>
  </id_info>
  <brief_title>Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics</brief_title>
  <official_title>Improving the Effectiveness of Treatment for Depression in Hispanics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether combination treatment driven by patient choice is better
      than standardized medication treatment at retaining and improving Hispanic patients with
      major depressive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retention of Hispanics in the treatment of major depressive disorder (MDD) continues to be a
      major public health problem. Hispanics drop out from treatment two to three times more
      frequently than non-Hispanic whites, despite the scarcity of treatment alternatives for
      Hispanics and their low rates of re-entry into the mental health care system. Consistent with
      the goals of Healthy People 2010 and the President's New Freedom Commission on Mental Health,
      the goal of this study is to test the efficacy in a research setting of a novel intervention
      to improve retention and response. This efficacy assessment would serve as a reference point
      for the development of future effectiveness trials in community settings.

      Our intervention is founded on growing evidence that when depressed Hispanics seek help for
      mental health problems, they prefer to receive psychotherapy or combined treatment in the
      form of weekly in-person clinic visits. However, socioeconomic barriers, such as low-paying
      jobs with irregular hours, lack of child care, and limited time availability, often reduce
      treatment retention and result in dropout rates up to three times those of non-Hispanic
      whites. Based on emerging literature and on promising pilot data, we propose to study the
      efficacy for depressed Hispanics of an intervention that would allow for patient choice
      between the following options: 1) Medication alone, following the Texas Medication Algorithm
      for Depression (TMA); 2) Brief Interpersonal Psychotherapy (IPT-B) alone, with optional
      telephone sessions; or 3) Combined medication plus IPT-B. This intervention would allow
      switching of treatment modality (e.g., from IPT-B alone to combined treatment) at any point
      during the study period. We hypothesize that by permitting patient choice among
      evidence-based treatments, flexibility in the sequential use of treatments, and novel
      treatment delivery systems, this intervention will substantially increase retention of
      Hispanics in MDD treatment. Furthermore, we will examine mediators and moderators of
      retention, including stigma and insurance coverage.

      We propose to test this intervention in depressed Hispanics seeking outpatient psychiatric
      treatment using a randomized trial with TMA as the control group. Both groups will have
      access to medication using the TMA but only one group will be offered IPT_B. . We will test
      the association between treatment, retention, and response over the course of acute MDD care
      (12 weeks), and will also obtain preliminary outcome data after 9 more months of treatment
      (i.e., for a total of 12 months). Our pilot data enable us to estimate the sample size for
      the acute phase, while the additional follow-up period allows us to examine the effect of
      choice over the longer-term course of MDD care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 10, 2014</completion_date>
  <primary_completion_date type="Actual">January 10, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Time of Retention</measure>
    <time_frame>52 weeks</time_frame>
    <description>Average number of weeks of retention of Hispanics in the treatment of MDD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Depression Scale (HAMD-17)</measure>
    <time_frame>Baseline</time_frame>
    <description>Hamilton Depression Scale (HAMD-17): Scoring is based on the 17-item scale of 0-4, the higher the worse.
0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression, over 24 severe depression
Minimum is 0 and the maximum score being 52</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>1 Texas Medication Algorithm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Patient Choice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressants through Texas Medication Algorithm (TMA)</intervention_name>
    <description>Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.</description>
    <arm_group_label>1 Texas Medication Algorithm</arm_group_label>
    <arm_group_label>2 Patient Choice</arm_group_label>
    <other_name>Celexa</other_name>
    <other_name>Lexapro</other_name>
    <other_name>Paxil</other_name>
    <other_name>Zoloft</other_name>
    <other_name>Effexor XR</other_name>
    <other_name>Wellbutrin</other_name>
    <other_name>Cymbalta</other_name>
    <other_name>Pamelor</other_name>
    <other_name>Remeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Interpersonal Psychotherapy (IPT-B)</intervention_name>
    <description>IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.</description>
    <arm_group_label>2 Patient Choice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hispanic males and females

          -  DSM-IV criteria for non-psychotic major depressive disorder (MDD) of at least moderate
             severity (HAM-D-17&gt; 18)

          -  18- 79

          -  Patients with stable dosage of Benzodiazepines to treat anxiety disorders

        Exclusion Criteria:

          -  At risk of attempting suicide

          -  Unstable medical illness

          -  History of bipolar disorder, schizophrenia, or other psychotic disorder

          -  Pregnant or lactating

          -  Alcohol or substance use disorder that requires acute detoxification
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Blanco, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <results_first_submitted>February 6, 2020</results_first_submitted>
  <results_first_submitted_qc>February 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2020</results_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Mark Olfson</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Mood Disorders</keyword>
  <keyword>Hispanic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant available to other researchers at this time.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1 Texas Medication Algorithm</title>
          <description>Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression
Antidepressants through Texas Medication Algorithm (TMA): Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.</description>
        </group>
        <group group_id="P2">
          <title>2 Patient Choice</title>
          <description>Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression
Antidepressants through Texas Medication Algorithm (TMA): Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
Brief Interpersonal Psychotherapy (IPT-B): IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 12</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 24</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 52</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Adult Hispanics with MDD</population>
      <group_list>
        <group group_id="B1">
          <title>1 Texas Medication Algorithm</title>
          <description>Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression
Antidepressants through Texas Medication Algorithm (TMA): Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.</description>
        </group>
        <group group_id="B2">
          <title>2 Patient Choice</title>
          <description>Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression
Antidepressants through Texas Medication Algorithm (TMA): Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
Brief Interpersonal Psychotherapy (IPT-B): IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="12.5"/>
                    <measurement group_id="B2" value="40.8" spread="11.2"/>
                    <measurement group_id="B3" value="39.5" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Time of Retention</title>
        <description>Average number of weeks of retention of Hispanics in the treatment of MDD</description>
        <time_frame>52 weeks</time_frame>
        <population>Adult Hispanics with MDD</population>
        <group_list>
          <group group_id="O1">
            <title>1 Texas Medication Algorithm</title>
            <description>Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression
Antidepressants through Texas Medication Algorithm (TMA): Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.</description>
          </group>
          <group group_id="O2">
            <title>2 Patient Choice</title>
            <description>Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression
Antidepressants through Texas Medication Algorithm (TMA): Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
Brief Interpersonal Psychotherapy (IPT-B): IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time of Retention</title>
          <description>Average number of weeks of retention of Hispanics in the treatment of MDD</description>
          <population>Adult Hispanics with MDD</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.08" spread="22.4"/>
                    <measurement group_id="O2" value="25.84" spread="20.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Scale (HAMD-17)</title>
        <description>Hamilton Depression Scale (HAMD-17): Scoring is based on the 17-item scale of 0-4, the higher the worse.
0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression, over 24 severe depression
Minimum is 0 and the maximum score being 52</description>
        <time_frame>Baseline</time_frame>
        <population>Adult Hispanics with MDD and Non-missing HAMD Total Score</population>
        <group_list>
          <group group_id="O1">
            <title>1 Texas Medication Algorithm</title>
            <description>Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression
Antidepressants through Texas Medication Algorithm (TMA): Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.</description>
          </group>
          <group group_id="O2">
            <title>2 Patient Choice</title>
            <description>Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression
Antidepressants through Texas Medication Algorithm (TMA): Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
Brief Interpersonal Psychotherapy (IPT-B): IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Scale (HAMD-17)</title>
          <description>Hamilton Depression Scale (HAMD-17): Scoring is based on the 17-item scale of 0-4, the higher the worse.
0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression, over 24 severe depression
Minimum is 0 and the maximum score being 52</description>
          <population>Adult Hispanics with MDD and Non-missing HAMD Total Score</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.89" spread="3.96"/>
                    <measurement group_id="O2" value="22.42" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 Texas Medication Algorithm</title>
          <description>Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression
Antidepressants through Texas Medication Algorithm (TMA): Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.</description>
        </group>
        <group group_id="E2">
          <title>2 Patient Choice</title>
          <description>Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression
Antidepressants through Texas Medication Algorithm (TMA): Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
Brief Interpersonal Psychotherapy (IPT-B): IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Olfson, MD, MPH</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-6413</phone>
      <email>mark.olfson@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

